Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228854 | 1.00 | ATM (0.56) | ATMELANECTSBCTSKCTRB1 | |
| SCHEMBL4394496 | 1.00 | ATM (0.56) | ATMELANECTSBCTSKCTRB1 | |
| SCHEMBL7279908 | 0.91 | ELANE (0.48) | ATMELANECTSBCTSKCTRB1 | |
| SCHEMBL7807991 | 0.90 | CASP3 (0.59) | CTSBCTSKCTSSCTSL | |
| SCHEMBL7807995 | 0.90 | CASP3 (0.59) | CTSBCTSKCTSSCTSL | |
| SCHEMBL7307323 | 0.87 | CTSL (0.58) | ATMELANECTSBCTSKCTRB1 | |
| SCHEMBL14341586 | 0.87 | CTSL (0.63) | CTSBCTSKCTSSCTSL | |
| SCHEMBL22754646 | 0.87 | ATM (0.54) | ATMELANECTSBCTSKCTRB1 | |
| SCHEMBL1844644 | 0.86 | CTSK (0.69) | CTSBCTSKCTSSCTSLPSMB1 | |
| SCHEMBL24187715 | 0.85 | ATM (0.58) | ATMELANECTSBCTSKCTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | ATM 3418/4885ELANE 614/4885CTSB 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.